Glucagon-like peptide-1 receptor agonists and risk of substance use disorders
Posted 29 May 2026
Dr Lisa Devine discusses a study examining the risk of substance use disorders and adverse related clinical events following glucagon-like peptide-1 receptor agonist initiation in people with no history, or with a pre-existing history, of substance use disorders, respectively.
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page